Study on Cognitive Disorders of Multiple Sclerosis

Phase 3 Completed 90 enrolled University Hospital, Caen H. Lundbeck A/S · collab Ministry of Health, France · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of Relapsing - Remitting multiple sclerosis. m

Timeline

Start: 2005-09
Primary completion: 2011-03
Completion: 2011-11

Publications

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori E, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	20 mg	—

Study on Cognitive Disorders of Multiple Sclerosis

Summary

Timeline

Publications

Drugs

Indications